We carefully select promising preclinical candidates and then work to achieve clinical proof of concept and create molecules on the cusp of becoming a drug. Here’s how we do it:
Our founders have deep, highly-credentialed experience designing innovative clinical development plans and executing rigorous clinical trials, including antibody-drug conjugates, novel biologics, and innovative small molecules.
We are veterans in global oncology drug research, development, commercialization and deal-making, and have built an extensive professional network within the worldwide oncology community. This enables us to forge win-win licensing partnerships for the most promising assets and license out proven therapies to our global pharmaceutical network.
Program
Modality / MOA
Indication
Discovery
Pre-Clinical
Phase I
OnCusp Rights
CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a highly stable and homogenous ADC. The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased “bystander effect” compared to competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight.
CUSP03 is a small molecule inhibitor to an RNA modifying enzyme that plays a critical role in driving large subsets of a hematologic malignancy, as well as a potential role in multiple solid tumors. This program is in lead optimization stage.
CUSP02 is a novel bispecific antibody that is designed to have important anti-tumor, immune-targeting and anti-angiogenic properties. This program is currently in early discovery.
Swipe To View
